000145647 001__ 145647 000145647 005__ 20241114112316.0 000145647 0247_ $$2doi$$a10.3390/biomedicines12102221 000145647 0248_ $$2sideral$$a140557 000145647 037__ $$aART-2024-140557 000145647 041__ $$aeng 000145647 100__ $$aGracia Aznar, Asun 000145647 245__ $$aPro-Resolving Inflammatory effects of a Marine Oil Enriched in specialized Pro-Resolving Mediators (SPMs) Supplement and its implication in patients with Post-COVID Syndrome (PCS) 000145647 260__ $$c2024 000145647 5060_ $$aAccess copy available to the general public$$fUnrestricted 000145647 5203_ $$aObjectives: This study aimed to evaluate the eicosanoid and pro-resolutive parameters in patients with Post-COVID Syndrome (PCS) during a 12-week supplementation with a marine oil enriched in specialized pro-resolving mediators (SPMs). Patient and methods: This study was conducted on 53 adult patients with PCS. The subjects included must have had a positive COVID-19 test (PCR, fast antigen test, or serologic test) and persistent symptoms related to COVID-19 at least 12 weeks before their enrolment in the study. The following parameters were evaluated: polyunsaturated fatty acids EPA, DHA, ARA, and DPA; specialized pro-resolving mediators (SPMs), 17-HDHA, 18-HEPE, 14-HDHA, resolvins, maresins, protectins, and lipoxins. The eicosanoids group included prostaglandins, thromboxanes, and leukotrienes. The development of the clinical symptoms of fatigue and dyspnea were evaluated using the Fatigue Severity Scale (FSS) and the Modified Medical Research Council (mMRC) Dyspnea Scale. Three groups with different intake amounts were evaluated (daily use of 500 mg, 1500 mg, and 3000 mg) and compared to a control group not using the product. Results: In the serum from patients with PCS, an increase in 17-HDHA, 18-HEPE, and 14-HDHA could be observed, and a decrease in the ratio between the pro-inflammatory and pro-resolutive lipid mediators was detected; both differences were significant (p < 0.05). There were no differences found between the three treatment groups. Fatigue and dyspnea showed a trend of improvement after supplementation in all groups. Conclusions: A clear enrichment in the serum of the three monohydroxylated SPMs could be observed at a dosage of 500 mg per day. Similarly, a clear improvement in fatigue and dyspnea was observed with this dosage. 000145647 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000145647 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000145647 700__ $$aMoreno Egea, Fernando 000145647 700__ $$aGracia Banzo, Rafael 000145647 700__ $$aGutierrez, Rocio 000145647 700__ $$aRizo, Jose Miguel 000145647 700__ $$aRodriguez-Ledo, Pilar 000145647 700__ $$0(orcid)0000-0001-6752-1992$$aNerin, Isabel$$uUniversidad de Zaragoza 000145647 700__ $$aRegidor, Pedro-Antonio 000145647 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000145647 773__ $$g12, 10 (2024), 2221 [19 pp.]$$tBiomedicines$$x2227-9059 000145647 8564_ $$s2668628$$uhttps://zaguan.unizar.es/record/145647/files/texto_completo.pdf$$yVersión publicada 000145647 8564_ $$s2816043$$uhttps://zaguan.unizar.es/record/145647/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000145647 909CO $$ooai:zaguan.unizar.es:145647$$particulos$$pdriver 000145647 951__ $$a2024-11-14-10:18:38 000145647 980__ $$aARTICLE